Providing hope in terminal cancer: when is it appropriate and when is it not?

作者: Han Chong Toh

DOI:

关键词: Psychological interventionMisinformationPsychotherapistMedicineContext (language use)DignityQuality of life (healthcare)PsychosocialOpen communicationIntervention (counseling)

摘要: Hope is essential in the face of terminal cancer. Generally Western societies, patients and their families prefer doctor to engage them transparent, realistic, authoritative, empathic open communication about diagnosis prognosis cancer but this topic not well studied Asian context. With exponential increase information many permutations treatment, rational otherwise, doctor-patient relationship even more critical planning best treatment strategy also rendering both particular general hope patient's war against Overall, majority drugs tested have failed reach market, those that have, only provide modest benefits, several major therapeutic breakthroughs notwithstanding. Commoditised medicalisation dying process ingrained into contemporary consciousness can potentially create unrealistic or false hope, nihilism a drain on resources patient society. These factors detract from dignity as an acceptable natural process. cannot be confined focusing merely existential dimension improving survival through technological intervention. Psychosocial and, where appropriate, spiritual interventions support play roles relieving suffering providing patient. victim misinformation self-interested external parties, nor obsession with just buying promises extending time without sufficient regard for quality life achieving good death.

参考文章(24)
H A Burris, M J Moore, J Andersen, M R Green, M L Rothenberg, M R Modiano, M C Cripps, R K Portenoy, A M Storniolo, P Tarassoff, R Nelson, F A Dorr, C D Stephens, D D Von Hoff, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology. ,vol. 15, pp. 2403- 2413 ,(1997) , 10.1200/JCO.1997.15.6.2403
Rebecca A. Miksad, Lowell Schnipper, Michael Goldstein, Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value Journal of Clinical Oncology. ,vol. 25, pp. 4506- 4507 ,(2007) , 10.1200/JCO.2007.13.0401
Jennifer W. Mack, Joanne Wolfe, E. Francis Cook, Holcombe E. Grier, Paul D. Cleary, Jane C. Weeks, Hope and Prognostic Disclosure Journal of Clinical Oncology. ,vol. 25, pp. 5636- 5642 ,(2007) , 10.1200/JCO.2007.12.6110
Paula Kim, Cost of Cancer Care: The Patient Perspective Journal of Clinical Oncology. ,vol. 25, pp. 228- 232 ,(2007) , 10.1200/JCO.2006.07.9111
Leonard B. Saltz, Progress in Cancer Care: The Hope, the Hype, and the Gap Between Reality and Perception Journal of Clinical Oncology. ,vol. 26, pp. 5020- 5021 ,(2008) , 10.1200/JCO.2008.17.6198
Miriam C. Morey, Denise C. Snyder, Richard Sloane, Harvey Jay Cohen, Bercedis Peterson, Terryl J. Hartman, Paige Miller, Diane C. Mitchell, Wendy Demark-Wahnefried, Effects of Home-Based Diet and Exercise on Functional Outcomes Among Older, Overweight Long-term Cancer Survivors JAMA. ,vol. 301, pp. 1883- 1891 ,(2009) , 10.1001/JAMA.2009.643
George J. Annas, Informed Consent, Cancer, and Truth in Prognosis The New England Journal of Medicine. ,vol. 330, pp. 223- 225 ,(1994) , 10.1056/NEJM199401203300324
Donald Oken, What to Tell Cancer Patients JAMA. ,vol. 175, pp. 1120- 1128 ,(1961) , 10.1001/JAMA.1961.03040130004002